William Martin-Doyle, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 6 | 2015 | 2245 | 0.920 |
Why?
|
| Cystectomy | 4 | 2015 | 686 | 0.530 |
Why?
|
| Electric Countershock | 1 | 2010 | 534 | 0.300 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 423 | 0.250 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2942 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 2728 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 2268 | 0.190 |
Why?
|
| Catheter Ablation | 2 | 2015 | 2758 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 11524 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 7913 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 520 | 0.110 |
Why?
|
| Ureteral Neoplasms | 1 | 2014 | 111 | 0.110 |
Why?
|
| Colitis | 1 | 2020 | 1170 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 931 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2014 | 309 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13695 | 0.100 |
Why?
|
| Hospitalization | 1 | 2010 | 10262 | 0.100 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 579 | 0.090 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 761 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 3479 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1378 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 1573 | 0.080 |
Why?
|
| Aorta | 1 | 2015 | 2061 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2015 | 1073 | 0.070 |
Why?
|
| Vitamin D | 1 | 2020 | 3223 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 9239 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 808 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 641 | 0.070 |
Why?
|
| Vincristine | 2 | 2018 | 1039 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6234 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2015 | 1922 | 0.060 |
Why?
|
| Carcinoma | 1 | 2014 | 2375 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2018 | 2242 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5510 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9583 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2018 | 2234 | 0.050 |
Why?
|
| Prognosis | 3 | 2017 | 29063 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 6895 | 0.050 |
Why?
|
| Humans | 13 | 2020 | 744343 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2015 | 40561 | 0.040 |
Why?
|
| Cisplatin | 2 | 2014 | 1662 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 4262 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 5034 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 3616 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20129 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2017 | 63114 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 15226 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 549 | 0.030 |
Why?
|
| Prednisone | 1 | 2017 | 1574 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 2617 | 0.030 |
Why?
|
| Survival Rate | 2 | 2018 | 12788 | 0.030 |
Why?
|
| Urothelium | 1 | 2014 | 277 | 0.030 |
Why?
|
| Male | 7 | 2020 | 350118 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 673 | 0.020 |
Why?
|
| Carboplatin | 1 | 2014 | 801 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2015 | 453 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15076 | 0.020 |
Why?
|
| Female | 7 | 2020 | 380194 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4933 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 806 | 0.020 |
Why?
|
| Middle Aged | 6 | 2020 | 213383 | 0.020 |
Why?
|
| Aged | 5 | 2020 | 163280 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1708 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2924 | 0.020 |
Why?
|
| Adult | 5 | 2018 | 214055 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 8340 | 0.010 |
Why?
|
| Thrombosis | 1 | 2017 | 2968 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9274 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11031 | 0.010 |
Why?
|
| United States | 1 | 2010 | 69872 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 168757 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18370 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 4034 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 56430 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57776 | 0.010 |
Why?
|
| Child | 1 | 2017 | 77709 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 85781 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 77449 | 0.010 |
Why?
|